Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Sci Rep. 2022 Jul 21;12(1):12480. doi: 10.1038/s41598-022-16700-7.
To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), 315 patients with locally advanced PC (clinical T-stage 3/4) were considered for analysis retrospectively. Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR 39.8-87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all p < 0.001). After propensity score-matching, there were 68 patients in each group. Among locally advanced PC patients, treatment with RP had a higher risk of biochemical recurrence compared to the RT group. In multivariate Cox regression analysis, treatment with RT plus ADT significantly decreased the risk of biochemical failure (HR 0.162, p < 0.001), but there was no significant difference in local recurrence, distant metastasis and overall survival (p = 0.470, p = 0.268 and p = 0.509, respectively). This information supported a clinical benefit in BCR control for patients undergoing RT plus long-term ADT compared to RP.
为了比较机器人辅助腹腔镜前列腺癌根治术(RP)与放射治疗(RT)联合长期雄激素剥夺疗法(ADT)治疗局部进展性前列腺癌(PC)的临床结局,回顾性分析了 315 例局部进展性 PC(临床 T 期 3/4 期)患者。采用 1:1 比例的倾向评分匹配法。中位随访时间为 59.2 个月(IQR 39.8-87.4)。RP 组 117 例(37.1%),RT 组 198 例(62.9%)。RT 组患者年龄较大,诊断时 PSA 较高,Gleason 评分较高,T 期较晚(均 P<0.001)。经过倾向评分匹配后,每组各有 68 例患者。在局部进展性 PC 患者中,与 RT 组相比,RP 治疗的生化复发风险更高。多因素 Cox 回归分析显示,RT 联合 ADT 治疗可显著降低生化失败风险(HR 0.162,P<0.001),但局部复发、远处转移和总生存无显著差异(P=0.470,P=0.268 和 P=0.509)。这些信息支持 RT 联合长期 ADT 治疗在 BCR 控制方面优于 RP。